Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has announced that the European Medicines Agency has validated its marketing authorization application for corifollitropin alfa, the company's experimental, sustained follicle stimulant. This application will follow the centralized procedure.
Subscribe to our email newsletter
Corifollitropin alfa is being developed as a potential treatment in controlled ovarian stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an assisted reproductive technology program.
Corifollitropin alfa is designed as a sustained follicle stimulant with the same pharmacodynamic profile as follicle stimulating hormone (FSH), but with a markedly prolonged duration of FSH activity, the company said. Due to its ability to initiate and sustain multiple follicular growth for an entire week, a single subcutaneous injection of the recommended dose of corifollitropin alfa may replace the first seven injections of FSH preparation in a COS treatment cycle.
If approved, corifollitropin alfa would extend Schering-Plough’s fertility portfolio, which also includes Puregon.